Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SKIN vs NWL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NWL Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 9–1 Matrix Metrics)

NWL Overall Winner 6-Pillar Tally: SKIN 3 – 3 NWL Matrix Metrics: SKIN 1 – 9 NWL

As of Nov 16, 2026, Newell Brands Inc. (NWL) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas NWL carries 48.5/100 (HOLD) at $5.85 (8.4x Forward P/E, 7.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SKIN vs NWL
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (314.8% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $12.50 · SMA50: $6.24
NWL NASDAQ Head-to-Head Winner
Newell Brands Inc.
Plastics Products, Nec
$5.85
+1.21% 1D
Market Cap $2.5B
TTM Revenue $7.31B
Forward P/E 8.4x
Beta / 30D Vol 1.28β · 76% Vol
Unified Composite Score
48.5 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 54.7 · SMA20: $5.60 · SMA50: $5.62

6-Pillar Scorecard Institutional Category Breakdown (SKIN 3 – 3 NWL)

Columns: Metric · SKIN · NWL
1. Valuation Multiples NWL
Forward P/E 106.4x 8.4x
Trailing P/E 106.4x 7.9x
PEG Ratio 0.93x 0.97x
EV / Revenue 0.9x 1.0x
2. Growth & Scale NWL
Revenue Growth (YoY) -2.1% +3.7%
Earnings Growth (YoY) +0.0% +126.6%
TTM Revenue (USD) $289M $7.31B
Market Cap $106.3M $2.5B
3. Profitability & Quality NWL
Gross Margin 67.2% 35.1%
Operating Margin 2.4% 7.8%
Net Profit Margin -6.3% -4.4%
Return on Equity (ROE) -30.1% -12.8%
4. Balance Sheet & Cash Flow SKIN
Cash Generation (TTM) $17M $53M
Cash Flow Margin 5.8% 0.7%
Net Cash / Leverage $161M Net Debt (6.61x D/E) $5.12B Net Debt (2.27x D/E)
Dividend Yield None (0.00%) 4.86%
5. Options & Positioning SKIN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 517.4% (100th %ile) 46.0% (48th %ile)
Put/Call OI Skew N/A 0.05x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 64.8% of Rev ($187M) 27.3% of Rev ($2.00B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Household & Personal Products Operator Household & Personal Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SKIN (1) vs NWL (9)
Institutional Metric SKIN NWL Criterion Row Edge
Market Capitalization
Scale
$106.3M $2.5B Larger Scale NWL
Trailing P/E Ratio
Valuation
106.4x 7.9x Lower Multiple NWL
Forward P/E Ratio
Valuation
106.4x 8.4x Lower Multiple NWL
Revenue Growth (YoY)
Growth
-2.1% +3.7% Higher Growth NWL
Operating Margin (TTM)
Profitability
2.4% 7.8% Higher Margin NWL
Net Profit Margin
Profitability
-6.3% -4.4% Higher Margin NWL
Return on Equity (ROE)
Capital Efficiency
-30.1% -12.8% Higher ROE NWL
52-Week Range Position
Momentum
83% ($0–$18) 67% ($3–$7) Stronger Trend SKIN
Beta / 30D Volatility
Risk Regime
-14.22β · 192% Vol 1.28β · 76% Vol Lower Realized Risk NWL
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 48.5 / 100 (HOLD) Higher Composite NWL
Trailing 12M Revenue (USD)
Operating Scale
$289M $7.31B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.2% 35.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.93x PEG · 0.9x EV/Rev 0.97x PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17M ($161M Net Debt (6.61x D/E)) $53M ($5.12B Net Debt (2.27x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +38.98 pp
SKIN: +42.52% · NWL: +3.54%
3M Horizon SKIN +2409.68 pp
SKIN: +2408.33% · NWL: -1.35%
6M Horizon SKIN +2324.87 pp
SKIN: +2385.14% · NWL: +60.27%
1Y Horizon SKIN +984.61 pp
SKIN: +1057.69% · NWL: +73.08%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SKIN Revenue NWL Revenue SKIN Op. Margin NWL Op. Margin Margin Leader
FY2018 N/A $10.2B N/A -74.4% NWL
FY2019 $170M $9.71B 8.1% -5.0% SKIN
FY2020 $120M $9.38B -14.4% -6.7% NWL
FY2021 $260M $10.6B -15.4% 9.6% NWL
FY2022 $370M $9.46B -7.1% 3.3% NWL
FY2023 $400M $8.13B -32.9% -1.0% NWL
FY2024 $330M $7.58B -20.3% 0.9% NWL
FY2025 $300M $7.20B -6.9% 0.5% NWL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NWL CONSOLIDATION
74d in phase · OBV NEUTRAL
Current IV 46.0%
IV Percentile 48th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NWL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published
NWL Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $2.5B market capitalization and 7.8% operating margin.
OpEx & R&D Reinvestment 27.3% of Rev ($2.00B)
90D Engineering Disclosures 0 Published

Investor FAQ SKIN vs NWL Key Questions & Quantitative Answers

As of Nov 16, 2026, Newell Brands Inc. (NWL) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas NWL carries 48.5/100 (HOLD) at $5.85 (8.4x Forward P/E, 7.8% operating margin). Technically, SKIN sits in a Markup phase (RSI 67.4, UNCLASSIFIED options structure) and NWL sits in a Neutral phase (RSI 54.7, CONSOLIDATION options structure).

NWL leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with NWL at +3.7% YoY revenue growth and +126.6% YoY earnings growth on $7.31B TTM revenue (35.1% gross margin, 7.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SKIN cumulative revenue shifted +76.5% while NWL shifted -29.1%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 27.3% of Rev ($2.00B) (0 disclosures) for NWL.

NWL screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas NWL trades at 8.4x Forward P/E, 7.9x Trailing P/E, 0.97x PEG, and 1.0x EV/Revenue (0.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus NWL (-12.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, NWL carries 46.0% implied volatility (48th %ile, Balanced (25th–60th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.